A MALE contraceptive must reduce the number of fertile sperm ejaculated sufficient to prevent fertilization. Hormonal methods aim to reduce sperm output reversibly through inhibiting pituitary gonadotropin secretion and consequent depletion of intratesticular testosterone. Testosterone-induced azoospermia provides highly effective and sustainable contraception (1); however only 65% of men treated with weekly testosterone enanthate (TE) injections become consistently azoospermic whereas the remainder exhibited various degrees of oligozoospermia (l-3). The explanation for the nonuniform induction of azoospermia by testosterone remains unknown however it has been proposed (4) that unfavorable pharmacokinetics of TE, the prototype androgen employed in most male contraceptive studies, lead to supraphysiological circulating testosterone levels that prevent the adequate depletion of intratesticular testosterone. The practical requirement for longer interinjection interval led to development of new long-acting depot testosterone preparations (5) but their effects on human spermatogenesis have not yet been determined. This study aimed to determine the effects of a long-acting depot testosterone preparation (6-8) on human spermatogenesis and test the hypothesis that steady-state testosterone levels within the physiological range might achieve azoospermia uniformly in fertile men.
Materials and Methods

Study design and procedures
The study aimed 1) to describe prospectively the effects of testosterone implants and 2) to compare retrospectively with men receiving weekly injections of 200 mg TE (Testoviron, Schering AG, Berlin, Germany) in the Sydney centre of a World Health Organization multicenter efficacy study of hormonal male contraception (1). The two studies drew from the same pool of volunteers but were consecutive in sequence rather than randomized.
Recruitment for the implant study commenced immediately after termination of intake to the WHO study. The design and overall outcomes for the WHO study have been described in detail elsewhere (1). In the implant study subjects provided two baseline sets of semen and blood samples at least 2 weeks apart before implantation of six 200 mg (total dose 1200 mg, release rate 9 mg/day) pellets of fused crystalline testosterone (Organon, Sydney, Australia) subdermally in the lower abdominal wall under local anaesthesia as described (7, 8 
Results
Subjects
The men entering the testosterone implant (n = 9) and WHO TE injection (n = 38) studies were similar in height, weight, body surface area, body mass index, and testis size and neither group differed significantly in these anthropometric variables from the control group of healthy men (n = 394) screened as potential sperm donors (data not shown). Implantation of testosterone pellets was very well tolerated (7, 8) and none of the men complained of any side-effects including changes in sexual function, bleeding, infection, or extrusion. Fused crystalline implants do not cause irritation or fibrosis unlike the compressed, cholesterol-containing pellets originally used in the United States (8). Among men having weekly TE injections, four discontinued within 4 months for medical reasons including two due to discomfort and intolerance of injection frequency and two due to acne. Acne (defined as any degree of typical pimples on back, chest, or face) was not observed in men having implants whereas it was common in men receiving TE injections (% ZIS. 25/38, p = 0.0004). Prostate-specific antigen rose by about 20% in the first 2 months after testosterone implantation returning subsequently to normal levels (P = 0.066). PSA levels were not measured in the TE study as blood samples were not consistently obtained before digital rectal examination of the prostate which may increase circulating PSA levels (13).
Sperm output
Pretreatment sperm density was similar in men entering the implant and TE injection studies (medians 123 ZIS. 107 M/mL, respectively) but both were significantly higher (P = 0.029 and 0.002, respectively) than among the healthy volunteers screened as potential sperm donors (median 74 M/ mL). This difference presumably reflects the selection bias for men with normal reproductive function required to enter these studies. Implants of testosterone sharply reduced sperm output (Fig. 1 ) which remained at near zero levels between the 2nd and 4th month after implantation.
Essentially identical patterns were observed whether expressed as concentrations or total output of motile, morphologically normal, or of all sperm. The fall in sperm output was similar to that observed among men having TE injections except that the rate of fall (expressed as a percentage of geometric mean baseline sperm density) was significantly greater at the first month in men bearing implants (17 + 6% ZX. 58 f 7%, P = 0.011). After the 5th month after testosterone implantation, sperm output returned to normal whereas mean sperm density remained suppressed on men continuing on TE injections. Similar proportions of men achieved azoospermia [5/9 (56%) DS. 25/38 (66%)] or severe oligozoospermia [Cl million sperm/ml, % (100%) IIS. 37/38 (97%)]. The implant study provided a power of 80% to exclude the hypothesis that testosterone implants consistently induce azoospermia but, due to the limited study sample size, the power was too low however to exclude an improved rate of achieving azoospermia but to less than 100%.
Reproductive hormones and SHBG After testosterone implantation, plasma testosterone levels increased (Fig. 2) but remained within the eugonadal range at each time-point apart from the 1st month for total testosterone (37.0 nM) and the 2nd month for free testosterone 
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(1015 PM) when levels just exceeded the upper limit of the eugonadal range (35 nM for total, 1000 PM for free testosterone). Plasma LH and FSH were suppressed to undetectable levels from the 1st until the 4th month when levels increased significantly by the 5th and returned to baseline by the 6th month. Plasma estradiol levels (Fig. 3) rose to peak at the 1st month but remained within the eugonadal range. Neither PRL nor SHBG levels changed significantly after testosterone implantation. After TE injections, plasma total and free testosterone and estradiol were markedly higher whereas PRL levels increased and SHBG levels fell (Table 1) . Plasma LH and FSH were both suppressed to virtually undetectable levels during continued treatment.
Metabolic effects of testosterone
The biochemical effects of testosterone on lipids, urea, calcium, albumin total protein, and hemoglobin were similar in magnitude for implants and TE injections; however due to larger sample size, these effects were statistically significant for TE injections only ( (23), this might maintain sufficient androgen effects on Sertoli cells to continue low levels of spermatogenesis. Although sex steroid levels were considerably higher in men having TE injections, these kinetic considerations also indicate that the nadir levels reported in this study at 7 days after the last TE injection actually underestimate the mean integrated testosterone levels to which subjects were exposed throughout the week during regular weekly TE injections.
Whereas the testosterone levels at 3 months after testosterone pellet implantation are also lower that peak levels (7, 8), this fall-off from peak testosterone levels is much less and therefore the discrepancy between integrated testosterone and estradiol levels on the two regimens is even greater than indicated by Table 1 .
Testosterone implants provide the first opportunity to test the effects of steady-state testosterone levels on normal human spermatogenesis.
These implants provide virually in men since steady-state testosterone levels which stayed mostly within the eugonadal range failed to achieve higher rates of azoospermia than did testosterone injections.
If the high-normal testosterone levels maintained by the testosterone implants in this study are still too high, then it is unclear if lower testosterone levels can be achieved that would still provide adequate androgen replacement and complete gonadotrophin suppression required for near-total inhibition of spermatogenesis. The failure of stable, physiological testosterone levels to produce azoospermia uniformly therefore argues that the reasons for the inconsistency of testosterone-induced azoospermia is more likely to reflect intrinsic differences in spermatogenesis rather than general metabolic actions of testosterone.
Another interesting finding from this study is that TE IMPLANTS AND HUMAN SPERMATOGENESIS 1331 injections induced more hormonal changes than did the testosterone implants. This is evident in the greater prevalante of acne as well as the decrease in SHBG and increase in PRL exhibited by men receiving TE injections compared with men having testosterone implants.
In contrast the biochemical effects were generally of similar magnitude.
Where hormonal effects were greater, this may relate to the supraphysiological testosterone and/or higher estradiol levels produced by regular TE injections compared with the more physiological levels maintained by the testosterone implants. It remains unclear whether these effects are due to testosterone itself or to its 5-a reduced metabolite, 5-a dihydrotestosterone (DHT), acting upon androgen receptors and/or upon estrogen receptors following aromatization of testosterone to estradiol. DHT levels were not measured in this study however it is unlikely that they differed between regimens. The subdermal implants are placed well below hair follicles which contain dermal 5-a reductase and transdermal passage of testosterone across truncal skin does not increase circulating DHT levels (36) in contrast with passage across scrotal skin where 5-a reductase levels are high (37). In any case our findings do indicate that the lower effective daily dose of testosterone produced by the depot testosterone preparation has the advantage of less hormonal side-effects while exhibiting the same degree of suppression of spermatogenesis. This dose-sparing effect of a steady-state formulation may reduce the risks of potential long-term side-effects of androgens such as cardiovascular or prostatic disease which need to be considered in relation to testosterone therapy.
